(S)-3-phenoxypyrrolidine | 931581-76-9

• 英文名称: (S)-3-phenoxypyrrolidine
• 英文别名: (3S)-3-phenoxypyrrolidine
• CAS: 931581-76-9
• 化学式: C₁₀H₁₃NO
• mdl: MFCD08688473
• 分子量: 163.219
• InChiKey: SKHPQIQATRHESG-JTQLQIEISA-N

物化性质

• 沸点：
  259.2±33.0 °C(Predicted)
• 密度：
  1.058±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  (S)-3-phenoxypyrrolidine 、 5-(2,4,5-trifluoro-3-hydroxyphenyl)-1,2,4-oxadiazole-3-carboxylic acid 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以6 %的产率得到(S)-(3-phenoxypyrrolidin-1-yl)(5-(2,4,5-trifluoro-3-hydroxyphenyl)-1,2,4-oxadiazol-3-yl)methanone
  参考文献：
  名称：

  WO2023/222850

  摘要：

  公开号：

文献信息

• PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20170327457A1

  公开（公告）日：2017-11-16

  The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.
• 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders
  申请人：JANSSEN PHARMACEUTICALS, INC.

  公开号：US20170333426A1

  公开（公告）日：2017-11-23

  The present invention relates to methods of treating various central nervous system disorders using novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.
• US8415350B2
  申请人：——

  公开号：US8415350B2

  公开（公告）日：2013-04-09
• US9737533B2
  申请人：——

  公开号：US9737533B2

  公开（公告）日：2017-08-22